Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis

Journal of Surgical Research

Volumn 168, Issue 1, 2011, Pages 97-102

  Yang, Jinfu ^a   Liao, Daguang ^a   Wang, Zhifei ^a   Liu, Feng ^a   Wu, Guangyong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Akt; glioma; mTOR; p27; prognosis; PTEN; S6

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P27; S6 KINASE;

ADULT; ARTICLE; CANCER SURVIVAL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CYTOPLASM; ENZYME PHOSPHORYLATION; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

BIOPSY; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 79955599554     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2009.06.025     Document Type: Article

References (21)

1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005;109:93.
2. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer 2000;88:2887.
3. Sun B, Chu D, Li W, et al. Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. J Neurooncol 2009 (in press).
4. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005;37:19.
5. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005;11:353.
6. Hardie DG. The AMP-activated protein kinase pathway new players upstream and downstream. J Cell Sci 2004;117:5479.
7. Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol 2005;17:158.
8. Law BK. Rapamycin: An anti-cancer immunosuppressant? Crit Rev Oncol Hematol 2005;56:47.
9. Shaw RJ, Bardeesy N, Manning BD. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004;6:91.
10. Pantuck AJ, Seligson DB, Klatte T. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer 2007;109:2257.
11. Strojnik T, Kos J, Zidanik B, et al. Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin Cancer Res 1999;5:559.
12. Levicar N, Nutall RK, Lah TT. Proteases in brain tumor progression. Acta Neurochir 2003;145:825.
13. Nutall TK, Pennington CJ, Taplin J, et al. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res 2003;1:333.
14. Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma: Occurrence, significance, and prognostic implications. Front Biosci 2000;5:D213.
15. Basanta D, Simon M, Hatzikirou H, Deutsch A. Evolutionary game theory elucidates the role of glycolysis in glioma progression and invasion. Cell Prolif 2008;41:980.
16. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287.
17. Amornphimoltham P, Patel V, Sodhi A, et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 2005;65:9953.
18. Bjornsti MA, Houghton PJ. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004;4:335.
19. Pene F, Claessens Y-E, Muller O. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002;21:6587.
20. Neshat MS, Mellinghoff IK, Tran C. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314.
21. Hidaka T, Hama S, Shrestha P, et al. The combination of low cytoplasmic and high nuclear expression of p27 predicts a better prognosis in high-grade astrocytoma. Anticancer Res 2009;29:597.